Alan Bash - 14 Aug 2026 Form 4 Insider Report for Legend Biotech Corp (LEGN)

Reporting relationship: Interim CEO
Issuer ticker: LEGN
Reported as of: 14 Aug 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 18 Aug 2026, 16:15:15 UTC
Prior SEC filing: 03 Aug 2026
Source filing: View source filing
Reporting owner signature: /s/ Robert Staloff, Attorney-in-Fact

Key filing fact

Alan Bash filed Form 4 for Legend Biotech Corp (LEGN) on 18 Aug 2026.

Key facts

This page summarizes Alan Bash's Form 4 filing for Legend Biotech Corp (LEGN).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 18 Aug 2026, 16:15.

Change

Previous filing in this sequence was filed on 03 Aug 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001908421 Primary reporting owner

BASH ALAN

Relationship: Interim CEO
Address: C/O LEGEND BIOTECH CORP, 77 CORPORATE DRIVE, 4TH FLOOR, BRIDGEWATER
Signature: /s/ Robert Staloff, Attorney-in-Fact
Signature date: 18 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

LEGN transaction

Ordinary Shares

Award

Transaction value
Shares: +4,908
Change %: +16%
Price: $0.000000^*
Shares after: 35,142
Date: 14 Aug 2026
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents two ordinary shares of the Issuer.

Footnote F2

Represents restricted share units (the "RSUs"). Each RSU represents a contingent right to receive one ordinary share of the Issuer upon settlement. 1/3 of the RSUs vest and becomes exercisable on each of July 27, 2027, July 27, 2028, and July 27, 2029, respectively, subject to the Reporting Person's continued service to the Issuer on each such vesting date.